366 related articles for article (PubMed ID: 28256054)
1. Lixisenatide reduces glycaemic variability in insulin-treated patients with type 2 diabetes.
Umpierrez GE; O'Neal D; DiGenio A; Goldenberg R; Hernandez-Triana E; Lin J; Park CY; Renard E; Kovatchev B
Diabetes Obes Metab; 2017 Sep; 19(9):1317-1321. PubMed ID: 28256054
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of lixisenatide in a predominantly Asian population with type 2 diabetes insufficiently controlled with basal insulin: The GetGoal-L-C randomized trial.
Yang W; Min K; Zhou Z; Li L; Xu X; Zhu D; Venkateshwar Rao A; Murthy LS; Zhang N; Li I; Niemoeller E; Shang S
Diabetes Obes Metab; 2018 Feb; 20(2):335-343. PubMed ID: 28742225
[TBL] [Abstract][Full Text] [Related]
3. Reduction of postprandial glucose by lixisenatide vs sitagliptin treatment in Japanese patients with type 2 diabetes on background insulin glargine: A randomized phase IV study (NEXTAGE Study).
Yamada Y; Senda M; Naito Y; Tamura M; Watanabe D; Shuto Y; Urita Y
Diabetes Obes Metab; 2017 Sep; 19(9):1252-1259. PubMed ID: 28345162
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of once-daily glucagon-like peptide-1 receptor agonist lixisenatide as an add-on treatment to basal insulin in Asian and white adults with type 2 diabetes mellitus: An individual-level pooled analysis of phase III studies.
Liu F; Liu Y; Liu M; Wu G; Zhang M; Zhang X; Cui N; Yin H; Chen L
J Diabetes Investig; 2021 Aug; 12(8):1386-1394. PubMed ID: 33475222
[TBL] [Abstract][Full Text] [Related]
5. Impact of baseline glycated haemoglobin, diabetes duration and body mass index on clinical outcomes in the LixiLan-O trial testing a titratable fixed-ratio combination of insulin glargine/lixisenatide (iGlarLixi) vs insulin glargine and lixisenatide monocomponents.
Davies MJ; Leiter LA; Guerci B; Grunberger G; Ampudia-Blasco FJ; Yu C; Stager W; Niemoeller E; Souhami E; Rosenstock J
Diabetes Obes Metab; 2017 Dec; 19(12):1798-1804. PubMed ID: 28432746
[TBL] [Abstract][Full Text] [Related]
6. Lixisenatide treatment improves glycaemic control in Asian patients with type 2 diabetes mellitus inadequately controlled on metformin with or without sulfonylurea: a randomized, double-blind, placebo-controlled, 24-week trial (GetGoal-M-Asia).
Yu Pan C; Han P; Liu X; Yan S; Feng P; Zhou Z; Lv X; Tian H; Jin Kui Y; Su B; Shang S; Niemoeller E
Diabetes Metab Res Rev; 2014 Nov; 30(8):726-35. PubMed ID: 24639432
[TBL] [Abstract][Full Text] [Related]
7. Insulin glargine/lixisenatide fixed-ratio combination improves glycaemic variability and control without increasing hypoglycaemia.
Aronson R; Umpierrez G; Stager W; Kovatchev B
Diabetes Obes Metab; 2019 Mar; 21(3):726-731. PubMed ID: 30421545
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of lixisenatide once daily versus placebo in type 2 diabetes insufficiently controlled on pioglitazone (GetGoal-P).
Pinget M; Goldenberg R; Niemoeller E; Muehlen-Bartmer I; Guo H; Aronson R
Diabetes Obes Metab; 2013 Nov; 15(11):1000-7. PubMed ID: 23627775
[TBL] [Abstract][Full Text] [Related]
9. How well do glucose variability measures predict patient glycaemic outcomes during treatment intensification in type 2 diabetes?
Inzucchi SE; Umpierrez G; DiGenio A; Zhou R; Kovatchev B
Diabetes Res Clin Pract; 2015 Apr; 108(1):179-86. PubMed ID: 25661664
[TBL] [Abstract][Full Text] [Related]
10. How well do glucose variability measures predict patient glycaemic outcomes during treatment intensification in type 2 diabetes?
Inzucchi SE; Umpierrez G; DiGenio A; Zhou R; Kovatchev B
Diabetes Res Clin Pract; 2015 Nov; 110(2):234-40. PubMed ID: 27049155
[TBL] [Abstract][Full Text] [Related]
11. Effect of once-weekly dulaglutide on glycated haemoglobin (HbA1c) and fasting blood glucose in patient subpopulations by gender, duration of diabetes and baseline HbA1c.
Gallwitz B; Dagogo-Jack S; Thieu V; Garcia-Perez LE; Pavo I; Yu M; Robertson KE; Zhang N; Giorgino F
Diabetes Obes Metab; 2018 Feb; 20(2):409-418. PubMed ID: 28817231
[TBL] [Abstract][Full Text] [Related]
12. Sensitivity of Traditional and Risk-Based Glycemic Variability Measures to the Effect of Glucose-Lowering Treatment in Type 2 Diabetes Mellitus.
Kovatchev B; Umpierrez G; DiGenio A; Zhou R; Inzucchi SE
J Diabetes Sci Technol; 2015 Jun; 9(6):1227-35. PubMed ID: 26078255
[TBL] [Abstract][Full Text] [Related]
13. Lixisenatide as add-on to oral anti-diabetic therapy: an effective treatment for glycaemic control with body weight benefits in type 2 diabetes.
Raccah D; Gourdy P; Sagnard L; Ceriello A
Diabetes Metab Res Rev; 2014 Nov; 30(8):742-8. PubMed ID: 24687427
[TBL] [Abstract][Full Text] [Related]
14. Effect of exenatide QW or placebo, both added to titrated insulin glargine, in uncontrolled type 2 diabetes: The DURATION-7 randomized study.
Guja C; Frías JP; Somogyi A; Jabbour S; Wang H; Hardy E; Rosenstock J
Diabetes Obes Metab; 2018 Jul; 20(7):1602-1614. PubMed ID: 29473704
[TBL] [Abstract][Full Text] [Related]
15. Glycaemic outcomes of an Individualized treatMent aPproach for oldER vulnerable patIents: A randomized, controlled stUdy in type 2 diabetes Mellitus (IMPERIUM).
Heller SR; Pratley RE; Sinclair A; Festa A; Kiljański J; Brusko CS; Duan R; Heine RJ
Diabetes Obes Metab; 2018 Jan; 20(1):148-156. PubMed ID: 28671753
[TBL] [Abstract][Full Text] [Related]
16. A 24-week study to evaluate the efficacy and safety of once-weekly dulaglutide added on to glimepiride in type 2 diabetes (AWARD-8).
Dungan KM; Weitgasser R; Perez Manghi F; Pintilei E; Fahrbach JL; Jiang HH; Shell J; Robertson KE
Diabetes Obes Metab; 2016 May; 18(5):475-82. PubMed ID: 26799540
[TBL] [Abstract][Full Text] [Related]
17. Pharmacodynamics of the glucagon-like peptide-1 receptor agonist lixisenatide in Japanese and Caucasian patients with type 2 diabetes mellitus poorly controlled on sulphonylureas with/without metformin.
Seino Y; Takami A; Boka G; Niemoeller E; Raccah D;
Diabetes Obes Metab; 2014 Aug; 16(8):739-47. PubMed ID: 24524806
[TBL] [Abstract][Full Text] [Related]
18. Long-term safety of once-daily lixisenatide in Japanese patients with type 2 diabetes mellitus: GetGoal-Mono-Japan.
Seino Y; Yabe D; Takami A; Niemoeller E; Takagi H
J Diabetes Complications; 2015; 29(8):1304-9. PubMed ID: 26342556
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of lixisenatide as add-on therapy to basal insulin in older adults with type 2 diabetes in the GetGoal-O Study.
Dailey GE; Dex TA; Roberts M; Liu M; Meneilly GS
J Diabetes; 2019 Dec; 11(12):971-981. PubMed ID: 31094074
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of liraglutide for overweight adult patients with type 1 diabetes and insufficient glycaemic control (Lira-1): a randomised, double-blind, placebo-controlled trial.
Dejgaard TF; Frandsen CS; Hansen TS; Almdal T; Urhammer S; Pedersen-Bjergaard U; Jensen T; Jensen AK; Holst JJ; Tarnow L; Knop FK; Madsbad S; Andersen HU
Lancet Diabetes Endocrinol; 2016 Mar; 4(3):221-232. PubMed ID: 26656289
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]